Fact CheckerSign in

NCT05922254Completed

Combined Effects of ACBT and AUTOGENIC DRAINAGE in Patients With Chronic Obstructive Pulmonary Disease

Combined Effects of Active Cycle of Breathing Technique and Autogenic Drainage in Patients With Chronic Obstructive Pulmonary Disease

Source: ClinicalTrials.gov · Last updated 27 Dec 2023

Brief summary (registry, in English)

A randomised controlled trial will be conducted with COPD patients as its target population. There will be 40 individuals for both the control group and the intervention group. Group A is a control group while Group B is an experimental group (20 participants on Group A and 20 on group B). The baseline treatment for both groups were pursed lip breathing and ACBT. On the other hand, group B experimental group will also undergo (pursued lip breathing and ACBT) with autogenic drainage. Group A session lasts for 30 minutes and Group B session lasts for 45 minutes. There is only one session per day. There is a three session in a week for 4 weeks. Measurements are made of dyspnea, oxygen saturation, peak expiratory flow rate, pulse rate and fatigue both before and after the treatment, data were recorded. Participants in the trial must have mild to moderate COPD (GOLD Criteria) and be between the ages of 40 to 60 years. Data from Sheikh Zayed Hospital, Rahim Yar Khan will be collected. Follow-up for both completed tasks and changes in pulmonary status will be evaluated after 4 weeks. Modified Borg Dyspnea (RPE) Scale, Breathlessness, Cough and Sputum Scale (BCSS), Fatigue Severity Scale or Visual Analogue Scale, Peak flow meter, Oximeter will be used to measure the outcomes. Data will be analysed using the SPSS 21.0 Statistical Software

Status (registry)
Completed
Study type
Interventional
Enrollment
40 (actual)
First submitted
6 Jun 2023
Start date
15 Jun 2023
Primary completion date
15 Sept 2023
Lead sponsor
Riphah International University
Diseases
COPD
NCT number
NCT05922254

What you commit to

  • Study type: Interventional
  • Participants enrolled: 40
  • From 15 Jun 2023 to the primary completion date, 15 Sept 2023
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Any recent surgery

Other illness

  • Cardiovascular impairment
  • Systemic illness
  • Angina
  • Uncontrolled diabetes and hypertension

Other

  • Patients having progressive respiratory muscle weakness (Mysthenia Gravis)
  • TB
  • Non-cooperative Patients

Who the study is looking for

  • Both genders (Male and Female)
  • Age 40 to 60 years
  • Mild to moderate COPD (According to GOLD Criteria)
  • Patient is bilingual.

Age in the registry: 40 years to 60 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Sheikh Zayed Hospital,
Coordinator of this site? Confirm its status
Rahim Yar KhanPakistanUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.